신규 바이오파마를 위한 환자용 기술 설계 : 주요 고려사항

This IDC Perspective explores the unique requirements of EBPs for patient-facing technology, maps the industry landscape, identifies key players involved, and provides guidance to the technology buyer on criteria to drive partnering decisions with patient-facing technology providers."This is the era of embedded unified patient experiences, and of flexible yet integrated solutions. Emerging biopharma will prioritize partners that are willing to customize and build specialized modules that adapt to the needs of niche or rare disease trials, that can embed novel solutions such as gamification or digital therapeutics designed to meet the needs of specific therapeutic areas, and that embed compliance in their product strategy. 'Patient centricity' was never as center stage as it is today, and EBPs are seeking out partners that are truly embedding the patient's voice in their product strategy and partners that are offering flexible pricing models and rapidly deployable solutions. This will help cash-strapped, yet highly innovative emerging biopharma to consolidate their position in the race to be first to market," said Dr. Nimita Limaye, research VP, Life Sciences R&D Strategy and Technology at IDC.

Executive Snapshot

Situation Overview

• Patient-Facing Technologies
  • Modular Solutions Versus Unified Platforms Versus Hybrid Solutions
    • Modular Solutions
    • Unified Platforms
    • Hybrid Approaches
  • The Evolving Landscape of Patient-Facing Technology Providers

Advice for the Technology Buyer

Learn More

• Related Research
• Synopsis